thalidomide has been researched along with Leukemia, Plasmacytic in 43 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide is an effective treatment for relapsed multiple myeloma (MM), but is associated with a significant side effect profile at higher doses." | 9.10 | Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. ( Abdalla, SH; Johnston, RE, 2002) |
| "We report the case of a 54-year-old African-American male with IgG multiple myeloma (MM) with disease resistant to multiple chemotherapy regimens and immunomodulatory treatment with thalidomide." | 8.82 | Unusual cutaneous involvement during plasma cell leukaemia phase in a multiple myeloma patient after treatment with thalidomide: a case report and review of the literature. ( Alexandrescu, DT; Koulova, L; Wiernik, PH, 2005) |
| "Treatment of multiple myeloma (MM) has significantly improved, although the disease remains incurable." | 5.43 | Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma? ( Berno, T; Cortelazzo, S; DE March, E; Marabese, A; Meneghini, V; Mian, M; Mondello, P; Patriarca, F; Pescosta, N; Pizzolo, G; Semenzato, G; Tinelli, M; Turri, G; Zambello, R, 2016) |
| "Primary plasma cell leukemia (PPCL) is a rare disease that progresses rapidly." | 5.40 | Successful bortezomib/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension. ( Fujimoto, T; Koyama, A; Kurihara, T; Nishikawa, A; Okamoto, Y; Shiotani, C; Tamura, S, 2014) |
| "Thalidomide is an effective treatment for relapsed multiple myeloma (MM), but is associated with a significant side effect profile at higher doses." | 5.10 | Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. ( Abdalla, SH; Johnston, RE, 2002) |
| "We report the case of a 54-year-old African-American male with IgG multiple myeloma (MM) with disease resistant to multiple chemotherapy regimens and immunomodulatory treatment with thalidomide." | 4.82 | Unusual cutaneous involvement during plasma cell leukaemia phase in a multiple myeloma patient after treatment with thalidomide: a case report and review of the literature. ( Alexandrescu, DT; Koulova, L; Wiernik, PH, 2005) |
| "Primary plasma cell leukemia (pPCL) is an aggressive plasma cell disorder characterized by circulating plasma cells and a poor prognosis." | 1.51 | Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. ( Boise, LH; Dhodapkar, MV; Gleason, C; Gupta, VA; Heffner, LT; Hofmeister, CC; Joseph, NS; Kaufman, JL; Lonial, S; Mina, R; Nooka, AK, 2019) |
| " Pomalidomide at a dosage of 4 mg orally on days 1-21 of repeated 28-day cycles associated with fixed low-dose dexamethasone (40 mg on days 1, 8, 15 and 22 of each 28-day cycle), outside of the clinical trials, was started as a final attempt." | 1.43 | Response to pomalidomide plus fixed low-dose dexamethasone in a case of secondary plasma cell leukaemia. ( Coppi, MR; Guaragna, G; Mele, G; Melpignano, A; Spina, A, 2016) |
| "Treatment of multiple myeloma (MM) has significantly improved, although the disease remains incurable." | 1.43 | Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma? ( Berno, T; Cortelazzo, S; DE March, E; Marabese, A; Meneghini, V; Mian, M; Mondello, P; Patriarca, F; Pescosta, N; Pizzolo, G; Semenzato, G; Tinelli, M; Turri, G; Zambello, R, 2016) |
| "Secondary monoclonal gammopathy of undetermined significance (MGUS) is a special phenomenon that occurs during the treatment of multiple myeloma (MM)." | 1.40 | Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias. ( An, G; Deng, S; Meng, H; Qiu, L; Shi, L; Sui, W; Wang, J; Xu, Y; Zhan, F; Zhu, G; Zou, D, 2014) |
| "Primary plasma cell leukemia (PPCL) is a rare disease that progresses rapidly." | 1.40 | Successful bortezomib/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension. ( Fujimoto, T; Koyama, A; Kurihara, T; Nishikawa, A; Okamoto, Y; Shiotani, C; Tamura, S, 2014) |
| "Bortezomib was given at standard doses and schedules, in various combinations with dexamethasone, thalidomide, doxorubicin, melphalan, prednisone, vincristine, and cyclophosphamide." | 1.38 | Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. ( D'Arena, G; Di Renzo, N; Falcone, A; Ferrara, F; Guariglia, R; Mansueto, G; Martorelli, MC; Mastrullo, L; Musto, P; Onofrillo, D; Pagano, L; Palumbo, A; Pietrantuono, G; Semenzato, G; Specchia, G; Valentini, CG; Venditti, A; Villani, O, 2012) |
| "A total of 128 cases of plasma cell leukemia were collected, and 73 of them (57%) were classified as primary (male/female 43/30)." | 1.37 | Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. ( Candoni, A; De Muro, M; De Stefano, V; Ferrara, F; Fianchi, L; Galieni, P; Gozzetti, A; Leone, G; Musto, P; Pagano, L; Petrucci, MT; Pogliani, EM; Pulsoni, A; Specchia, G; Valentini, CG; Venditti, A; Visani, G; Visco, C, 2011) |
| "Plasma cell leukemia is a rare, aggressive form of multiple myeloma." | 1.36 | A rare case of plasma cell leukemia in a 35 year old. ( Ambaliya, A; Dosi, RV; Joshi, HJ; Patell, RD, 2010) |
| "Primary plasma cell leukemia (PCL) is a rare hematologic disorder with distinct features." | 1.34 | Nonsecretory primary plasma cell leukemia with good response to thalidomide-based treatment. ( Atta, J; Brück, P; Bühme, A; Hoelzer, D; Mousset, S, 2007) |
| "Sustained ventricular tachycardia possibly owing to thalidomide treatment." | 1.34 | Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia. ( Ballanti, S; Berchicci, L; Bolli, N; Capolsini, I; Giordano, G; Lotti, F; Mastrodicasa, E; Merigiola, C; Tabilio, A, 2007) |
| "Multiple myeloma is a B-cell malignancy characterized by proliferation of neoplastic plasma cells." | 1.31 | A case of aggressive multiple myeloma with cleaved, multilobated, and monocytoid nuclei, and no serum monoclonal gammopathy. ( Butch, AW; Flick, JT; Pappas, AA; Yeh, YA, 2000) |
| "Thalidomide has recently enjoyed renewed interest as a treatment in many disorders, including plasma cell leukemia." | 1.31 | Thalidomide-associated hepatitis: a case report. ( Fowler, R; Imrie, K, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (44.19) | 29.6817 |
| 2010's | 23 (53.49) | 24.3611 |
| 2020's | 1 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kasinathan, G | 1 |
| Tian, C | 1 |
| Yang, H | 1 |
| Zhu, L | 1 |
| Zhang, Q | 1 |
| Cao, Z | 1 |
| Zhang, Y | 1 |
| Mina, R | 2 |
| Joseph, NS | 1 |
| Kaufman, JL | 1 |
| Gupta, VA | 1 |
| Heffner, LT | 1 |
| Hofmeister, CC | 1 |
| Boise, LH | 1 |
| Dhodapkar, MV | 1 |
| Gleason, C | 1 |
| Nooka, AK | 1 |
| Lonial, S | 1 |
| Mangiacavalli, S | 1 |
| Pochintesta, L | 1 |
| Cocito, F | 1 |
| Pompa, A | 1 |
| Bernasconi, P | 1 |
| Cazzola, M | 1 |
| Corso, A | 1 |
| Ueda, S | 1 |
| Kubo, M | 1 |
| Matsuura, N | 1 |
| Matsunaga, H | 1 |
| Kataoka, S | 1 |
| Maeda, T | 1 |
| Inui, Y | 1 |
| Kawata, S | 1 |
| Kanakura, Y | 1 |
| Musto, P | 6 |
| Simeon, V | 1 |
| Martorelli, MC | 3 |
| Petrucci, MT | 3 |
| Cascavilla, N | 1 |
| Di Raimondo, F | 1 |
| Caravita, T | 2 |
| Morabito, F | 1 |
| Offidani, M | 1 |
| Olivieri, A | 2 |
| Benevolo, G | 1 |
| Guariglia, R | 3 |
| D'Arena, G | 3 |
| Mansueto, G | 2 |
| Filardi, N | 1 |
| Nobile, F | 1 |
| Levi, A | 2 |
| Falcone, A | 2 |
| Cavalli, M | 1 |
| Pietrantuono, G | 3 |
| Villani, O | 3 |
| Bringhen, S | 1 |
| Omedè, P | 1 |
| Lerose, R | 2 |
| Agnelli, L | 1 |
| Todoerti, K | 1 |
| Neri, A | 1 |
| Boccadoro, M | 1 |
| Palumbo, A | 2 |
| Zou, D | 1 |
| An, G | 1 |
| Zhu, G | 1 |
| Wang, J | 1 |
| Shi, L | 1 |
| Meng, H | 1 |
| Xu, Y | 1 |
| Sui, W | 1 |
| Deng, S | 1 |
| Zhan, F | 1 |
| Qiu, L | 1 |
| Tamura, S | 1 |
| Koyama, A | 1 |
| Shiotani, C | 1 |
| Kurihara, T | 1 |
| Nishikawa, A | 1 |
| Okamoto, Y | 1 |
| Fujimoto, T | 1 |
| Jimenez-Zepeda, VH | 1 |
| Reece, DE | 1 |
| Trudel, S | 1 |
| Chen, C | 1 |
| Tiedemann, R | 1 |
| Kukreti, V | 1 |
| Tan, J | 1 |
| Lam-Po-Tang, M | 1 |
| Hutchison, CA | 1 |
| de Zoysa, JR | 1 |
| Fabbro, SK | 1 |
| Kaffenberger, BH | 1 |
| Sekiguchi, Y | 1 |
| Shimada, A | 1 |
| Wakabayashi, M | 1 |
| Sugimoto, K | 1 |
| Tomita, S | 1 |
| Izumi, H | 1 |
| Nakamura, N | 1 |
| Sawada, T | 1 |
| Ohta, Y | 1 |
| Komatsu, N | 1 |
| Noguchi, M | 1 |
| Ravinet, A | 1 |
| Bay, JO | 1 |
| Tournilhac, O | 1 |
| Hanbali, A | 1 |
| Alrajeh, A | 1 |
| Rasheed, W | 1 |
| Mele, G | 1 |
| Coppi, MR | 1 |
| Guaragna, G | 1 |
| Spina, A | 1 |
| Melpignano, A | 1 |
| Mian, M | 1 |
| Tinelli, M | 1 |
| DE March, E | 1 |
| Turri, G | 1 |
| Meneghini, V | 1 |
| Pescosta, N | 1 |
| Berno, T | 1 |
| Marabese, A | 1 |
| Mondello, P | 1 |
| Patriarca, F | 1 |
| Pizzolo, G | 1 |
| Semenzato, G | 2 |
| Cortelazzo, S | 1 |
| Zambello, R | 1 |
| Attolico, I | 1 |
| Cimminiello, M | 1 |
| Discepoli, G | 1 |
| Cifarelli, RA | 1 |
| Pretz, J | 1 |
| Medeiros, BC | 2 |
| Abe, M | 1 |
| Yokoyama, H | 1 |
| Tohmiya, Y | 1 |
| Okitsu, Y | 1 |
| Ohguchi, H | 1 |
| Kohata, K | 1 |
| Yamamoto, J | 1 |
| Onishi, Y | 1 |
| Ishizawa, K | 1 |
| Kameoka, J | 1 |
| Harigae, H | 1 |
| Sher, T | 1 |
| Miller, KC | 1 |
| Deeb, G | 1 |
| Lee, K | 1 |
| Chanan-Khan, A | 1 |
| Liedtke, M | 1 |
| Pagano, L | 2 |
| Valentini, CG | 2 |
| De Stefano, V | 1 |
| Venditti, A | 2 |
| Visani, G | 1 |
| Candoni, A | 1 |
| Specchia, G | 2 |
| Visco, C | 1 |
| Pogliani, EM | 1 |
| Ferrara, F | 2 |
| Galieni, P | 1 |
| Gozzetti, A | 2 |
| Fianchi, L | 1 |
| De Muro, M | 1 |
| Leone, G | 1 |
| Pulsoni, A | 1 |
| Onofrillo, D | 1 |
| Di Renzo, N | 1 |
| Mastrullo, L | 1 |
| Defina, M | 1 |
| D'Auria, F | 2 |
| Papini, G | 1 |
| Statuto, T | 1 |
| Steduto, T | 1 |
| Bocchia, M | 1 |
| Siniscalchi, A | 1 |
| Tendas, A | 1 |
| Morino, L | 1 |
| Dentamaro, T | 1 |
| De Bellis, A | 1 |
| Perrotti, A | 1 |
| de Fabritiis, P | 1 |
| Dosi, RV | 1 |
| Ambaliya, A | 1 |
| Patell, RD | 1 |
| Joshi, HJ | 1 |
| Miwa, A | 1 |
| Tsiara, S | 1 |
| Chaidos, A | 1 |
| Kapsali, H | 1 |
| Tzouvara, E | 1 |
| Bourantas, KL | 1 |
| Ural, AU | 1 |
| Yilmaz, MI | 1 |
| Avcu, F | 1 |
| Pekel, A | 1 |
| Zerman, M | 1 |
| Nevruz, O | 1 |
| Sengul, A | 1 |
| Yalcin, A | 1 |
| Wöhrer, S | 1 |
| Ackermann, J | 1 |
| Baldia, C | 1 |
| Seidl, S | 1 |
| Raderer, M | 1 |
| Simonitsch, I | 1 |
| Drach, J | 1 |
| Alexandrescu, DT | 1 |
| Koulova, L | 1 |
| Wiernik, PH | 1 |
| Saka, B | 1 |
| Erten, N | 1 |
| Oztürk, G | 1 |
| Yilmaz, C | 1 |
| Dogan, O | 1 |
| Buyukbabani, N | 1 |
| Besisik, SK | 1 |
| Lommatzsch, SE | 1 |
| Bellizzi, AM | 1 |
| Cathro, HP | 1 |
| Rosner, MH | 1 |
| Gertz, MA | 1 |
| Martini, V | 1 |
| Gallucci, C | 1 |
| Palumbo, G | 1 |
| Del Bianco, P | 1 |
| Torromeo, C | 1 |
| Foà, R | 1 |
| Benson, DM | 1 |
| Smith, MK | 1 |
| Brück, P | 1 |
| Mousset, S | 1 |
| Bühme, A | 1 |
| Hoelzer, D | 1 |
| Atta, J | 1 |
| Ballanti, S | 1 |
| Mastrodicasa, E | 1 |
| Bolli, N | 1 |
| Lotti, F | 1 |
| Capolsini, I | 1 |
| Berchicci, L | 1 |
| Merigiola, C | 1 |
| Giordano, G | 1 |
| Tabilio, A | 1 |
| Zonno, A | 1 |
| Yeh, YA | 1 |
| Pappas, AA | 1 |
| Flick, JT | 1 |
| Butch, AW | 1 |
| Fowler, R | 1 |
| Imrie, K | 1 |
| Johnston, RE | 1 |
| Abdalla, SH | 1 |
| Bauduer, F | 1 |
5 reviews available for thalidomide and Leukemia, Plasmacytic
| Article | Year |
|---|---|
Stringent complete remission of primary plasma cell leukemia with reduced-dose bortezomib, lenalidomide and dexamethasone: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Respo | 2013 |
[Plasma cell leukemia].
Topics: Aged; Antineoplastic Agents; Biomedical Research; Boronic Acids; Bortezomib; Female; Hematopoietic S | 2014 |
Plasma cell leukaemia and other aggressive plasma cell malignancies.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Leukemia, Plas | 2010 |
Plasma cell leukemia: concepts and management.
Topics: Aged; Antigens, CD20; Antineoplastic Agents; Boronic Acids; Bortezomib; CD56 Antigen; Humans; Lenali | 2010 |
Unusual cutaneous involvement during plasma cell leukaemia phase in a multiple myeloma patient after treatment with thalidomide: a case report and review of the literature.
Topics: Humans; Immunosuppressive Agents; Leukemia, Plasma Cell; Leukemic Infiltration; Male; Middle Aged; M | 2005 |
2 trials available for thalidomide and Leukemia, Plasmacytic
| Article | Year |
|---|---|
Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Humans; Leukemia, Plasma Cell; Male | 2007 |
Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Blood Cell Count; Dose-Response Relationship, Drug; Female; Humans; | 2002 |
36 other studies available for thalidomide and Leukemia, Plasmacytic
| Article | Year |
|---|---|
Primary plasma cell leukaemia in a 39-year-old man.
Topics: Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Marrow; Bortezomib; Dexamethaso | 2020 |
Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; B | 2017 |
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chemothe | 2019 |
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, | 2013 |
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.
Topics: Adult; Aged; Aged, 80 and over; Dexamethasone; Female; Humans; Lenalidomide; Leukemia, Plasma Cell; | 2014 |
Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Prog | 2014 |
Successful bortezomib/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Huma | 2014 |
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Le | 2015 |
Extended high cut-off haemodialysis for myeloma cast nephropathy in Auckland, 2008-2012.
Topics: Aged; Antineoplastic Agents; Antineoplastic Protocols; Biopsy; Boronic Acids; Bortezomib; Dexamethas | 2014 |
Resident rounds part III: plasma cell leukemia with initial cutaneous presentation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Bortezomib; Dexamethasone; | 2014 |
A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Examination; Boronic | 2014 |
Plasma cell leukemia mimicking hairy cell leukemia.
Topics: Adult; Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; Bortezomib; Cyclophosphamide | 2015 |
Response to pomalidomide plus fixed low-dose dexamethasone in a case of secondary plasma cell leukaemia.
Topics: Aged; Dexamethasone; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Plasma Cell; Thalid | 2016 |
Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma?
Topics: Bortezomib; Humans; Lenalidomide; Leukemia, Plasma Cell; Multiple Myeloma; Prognosis; Retrospective | 2016 |
Lenalidomide can induce graft versus leukemia effect in primary plasma cell leukemia: a case report.
Topics: Adult; Antineoplastic Agents; Female; Graft vs Leukemia Effect; Humans; In Situ Hybridization, Fluor | 2009 |
Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy.
Topics: Aged; Antineoplastic Agents; Female; Humans; Lenalidomide; Leukemia, Plasma Cell; Pulmonary Eosinoph | 2009 |
Plasma cell leukemia maintaining complete remission by syngeneic stem cell transplantation combined with low-dose thalidomide maintenance therapy.
Topics: Adult; Combined Modality Therapy; Humans; Leukemia, Plasma Cell; Male; Remission Induction; Stem Cel | 2009 |
Primary plasma cell leukemia: a retrospective multicenter study of 73 patients.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boro | 2011 |
Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2012 |
Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Fata | 2012 |
Lenalidomide cutaneous adverse event: a case of Stevens-Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Eruptions; Humans; Lenalidomide; | 2012 |
A rare case of plasma cell leukemia in a 35 year old.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Plasma Cell; Male; Melphala | 2010 |
[Diagnosis and treatment for plasma cell leukemia].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An | 2012 |
Thalidomide administration for the treatment of resistant plasma cell leukemia.
Topics: Adjuvants, Immunologic; Aged; Angiogenesis Inhibitors; Drug Tolerance; Female; Humans; Leukemia, Pla | 2003 |
The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide.
Topics: Antineoplastic Agents; Apoptosis; Calcium; Cell Cycle; Cell Division; Dexamethasone; Diphosphonates; | 2003 |
Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone - a case report.
Topics: Adult; Antineoplastic Agents; Dexamethasone; Female; Humans; Leukemia, Plasma Cell; Thalidomide; Tre | 2004 |
Kappa light chain myeloma with initial cutaneous involvement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dexamethasone; Drug Resistance, Neoplas | 2006 |
Acute renal failure caused by renal infiltration by hematolymphoid malignancy.
Topics: Acute Kidney Injury; Allopurinol; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; D | 2006 |
Managing plasma cell leukemia.
Topics: Angiogenesis Inhibitors; Genetic Heterogeneity; Humans; Leukemia, Plasma Cell; Thalidomide; Treatmen | 2007 |
Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia.
Topics: Female; Humans; Kinetics; Lenalidomide; Leukemia, Plasma Cell; Middle Aged; Thalidomide; Treatment O | 2007 |
Nonsecretory primary plasma cell leukemia with good response to thalidomide-based treatment.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Humans; | 2007 |
Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.
Topics: Aged; Angiogenesis Inhibitors; Humans; Leukemia, Plasma Cell; Male; Tachycardia, Ventricular; Thalid | 2007 |
Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Immunologic Factors; Le | 2008 |
A case of aggressive multiple myeloma with cleaved, multilobated, and monocytoid nuclei, and no serum monoclonal gammopathy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cell Cycle; Cisplatin; Cycl | 2000 |
Thalidomide-associated hepatitis: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liv | 2001 |
Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma.
Topics: Aged; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, P | 2002 |